Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
November 2024
Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial
JAAD. 2024. Epub ahead of print DOI: 10.1016/j.jaad.2024.09.074
Werth et al. demonstrated that iberdomide significantly improved cutaneous lupus erythematosus (CLE) outcomes, particularly in subacute and chronic CLE patients, by reducing Cutaneous Lupus Area and Severity Index Activity (CLASI-A) scores. The study showed continued efficacy through 24 weeks, with the 0.45 mg dose providing the greatest improvement in patients with severe baseline scores, and iberdomide was well-tolerated over 104 weeks.
Keywords:
October 2024
Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study
RMD Open 2024;10:e004437 DOI: 10.1136/rmdopen-2024-004437
Pappa et al. explored the achievement of EULAR/ERA-EDTA targets in lupus nephritis patients receiving standard immunosuppressive therapy. Two-thirds of the cohort achieved target responses by 12 months, but 20% required therapy modifications due to suboptimal outcomes.
April 2024
CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up
N Engl J Med 2024;390(8):687–700 DOI 10.1056/NEJMoa2308917
In this case series by Müller, et al., eight patients who received a CD19 CAR T-cell infusion achieved Definition of Remission in SLE (DORIS) remission, Lupus Low Disease Activity State and a SLEDAI 2K score of 0 at 6 months post-infusion. Long-term follow-up through 24 months showed that SLE disease activity remained absent
in all eight patients.